Investigational drug · Phase 3
RVX000222
Also called: apabetalone, RVX-208
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Post-Acute COVID-19 Syndrome, Kidney Failure, Chronic.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "RVX000222"
First trial start
2024
Nov 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RVX000222", any sponsor or status.
Conditions studied
As listed on its trial records.
- Post-Acute COVID-19 Syndrome
- Kidney Failure, Chronic
Approved drugs for the same conditions: COVID-19 · Infectious disease and vaccines · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "RVX000222" as an intervention, largest first.
- Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CADPivotal-lookingCompleted
Resverlogix CorpIndustry
NCT02586155 · 2,425 participants · Start Nov 2015 · Primary completion Nov 30, 2020
Drug: Apabetalone; Placebo and 2 more · For: Diabetes Mellitus, Type 2; Coronary Artery Disease
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; Coronel Suárez, Argentina · 214 sites in all
- ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression EvaluationPivotal-lookingCompleted
Resverlogix CorpIndustry
NCT01067820 · 324 participants · Start Sep 2011 · Primary completion May 2013
Drug: RVX000222; Placebo RVX000222 · For: Coronary Artery Disease
Sites: La Plata, Argentina; Buenos Aires, Argentina; Corrientes, Argentina · 58 sites in all
- Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery DiseasePivotal-lookingCompleted
Resverlogix CorpIndustry
NCT01058018 · 299 participants · Start Dec 2009 · Primary completion Jun 2010
Drug: RVX000222; Placebo · For: Atherosclerosis; Coronary Artery Disease
Sites: Tustin, California
- A Study of Apabetalone in Subjects With Long -COVIDPivotal-lookingRecruiting
Resverlogix CorpIndustry
NCT06590324 · 200 participants (planned) · Start Apr 15, 2025 · Primary completion Dec 30, 2025
Drug: Apabetalone · For: Post-Acute COVID-19 Syndrome
Sites: Amman, Jordan; Al Mubarraz, Saudi Arabia; Dubai, United Arab Emirates
- The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I StimulationPivotal-lookingCompleted
Resverlogix CorpIndustry
NCT01423188 · 176 participants · Start Aug 2011 · Primary completion Jun 2012
Drug: RVX000222; Placebo RVX000222 · For: Coronary Artery Disease; Dyslipidemia
Sites: East Burger Street, South Africa; Westdene, South Africa; Goodwood, South Africa · 25 sites in all
- Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL CholesterolCompleted
Resverlogix CorpIndustry
NCT00768274 · 72 participants · Start Sep 2008 · Primary completion Aug 2009
Drug: RVX000222; Placebo · For: Dyslipidemia; Atherosclerosis; Acute Coronary Syndrome and 1 more
Sites: Dallas, Texas
- A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With HemodialysisNot yet recruiting
Resverlogix CorpIndustry
NCT03160430 · 44 participants (planned) · Start Nov 22, 2024 · Primary completion Nov 22, 2026
Drug: apabetalone; Placebos · For: Kidney Failure, Chronic
Resverlogix CorpIndustry
NCT01728467 · 20 participants · Start Nov 2012 · Primary completion Mar 2014
Drug: RVX000222; Placebo, RVX000222 · For: Diabetes
Sites: Melbourne, Australia
- Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in DyslipidemiaTerminated
Resverlogix CorpIndustry
NCT01863225 · 13 participants · Start May 2013 · Primary completion Jun 2013
Drug: RVX000222; Rosuvastatin and 3 more · For: Dyslipidemia; Coronary Artery Disease
Sites: Adelaide, Australia
Resverlogix CorpIndustry
NCT03228940 · 0 participants · Start Nov 22, 2022 · Primary completion Nov 22, 2022
Drug: RVX000222 · For: Fabry Disease
Sites: Halifax, Canada
Newest research
PubMed records naming it or its code names, newest first.
- Reprogramming macrophage polarization via CD44-targeted and ROS-responsive apabetalone-loaded micelles for rheumatoid arthritis treatment.
Huang JF, Qin W, Xiao DM, et al. · Int J Pharm X 2026
- Systemic RVX-208 Attenuates Experimental Periodontitis Through Inflammatory Host Modulation.
Alam S, Ansari S, Yilmaz BT, et al. · J Periodontal Res 2026
- Apabetalone mediates HIV-1 transcriptional activation and clearance of latently infected cells via LncRNA OSER1-AS1.
Song B, Lin X, Cao L, et al. · Gene 2026
- BD2-selective BRD4 inhibitor ZX29 mitigates myocardial ischemia-reperfusion injury via BRD4-YY1-NCOA4 axis disruption and ferroptosis inhibition.
Li Z, Xin M, Wu Z, et al. · Acta Pharm Sin B 2026
- BET inhibitor apabetalone suppresses the fibrotic activation of cardiac fibroblasts associated with heart dysfunction.
Wasiak S, Gilham D, Fu L, et al. · Biomed Pharmacother 2026
- Metabolite sensing in cardiometabolic HFpEF: mechanisms and therapeutic perspectives.
Fan Y, Wang X, Ai S, et al. · Diabetes Res Clin Pract 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.